Skip to main content

Table 1 Clinical characteristics of patients in Nanostring cohort after QC and normalisation

From: Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach

Characteristic

 

All (N = 158)

Responder (N = 90)

Non-responder (N = 68)

P-value

Patients with repeats, N

 

5

3

2

 

Additional repeats, No

7

4

3

 

Treatment, N. (%):

IPI + PD1c

74 (46.8)

47 (52.2)

27 (39.7)

0.1615a

PD1c

84 (53.2)

43 (47.8)

41 (60.3)

Biopsy sites, N. (%):

    

0.1461b

 

Brain

15 (9.5)

9 (10)

6 (8.8)

 

Liver

2 (1.3)

2 (2.2)

 
 

Lung

7 (4.4)

4 (4.4)

3 (4.4)

 

Lymph node

44 (27.8)

21 (23.3)

23 (33.8)

 

Mucosa

2 (1.3)

 

2 (2.9)

 

Primary

6 (3.8)

5 (5.6)

1 (1.5)

 

Small bowel

3 (1.9)

2 (2.2)

1 (1.5)

 

Subcutaneous

73 (46.2)

41 (45.6)

32 (47.1)

 

Other

6 (3.8)

6 (6.7)

 
  1. N indicates number
  2. aPearson’s Chi-squared test with Yates’ continuity correction
  3. bPearson’s Chi-squared test
  4. cIPI: ipilimumab; PD1: nivolumab or pembrolizumab